Clinical trial • Phase I • Immunology
PF-08065010 for Rheumatoid arthritis | Systemic lupus erythematosus
Phase I trial of PF-08065010 for Rheumatoid arthritis | Systemic lupus erythematosus. 100 participants.
Overview
- Trial Therapeutic Area
- Immunology
- Trial Disease
- Rheumatoid arthritis | Systemic lupus erythematosus
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 26-02-2026
- First CTIS Authorization Date
- 17-03-2026
Trial design
Phase I trial across 1 site in Belgium.
- Target Sample Size
- 100
Recruitment
- Planned Sample Size
- 100
- Recruitment Window Months
- 16
Methods
- Site contact: Pfizer Clinical Research Unit, Route de Lennik 808, Brussels — email PfizerVolRecruitment@pfizer.com, phone +3225567003 (Belgium)
- Sponsor public contact: Clinical Medical Lead — email ClinicalTrials.gov_Inquiries@pfizer.com, phone +18007181021
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 100
Belgium
- Earliest CTIS Part Ii Submission Date
- 27-02-2026
- Latest Decision Or Authorization Date
- 17-03-2026
- Processing Time Days
- 18
- Number Of Sites
- 1
- Number Of Participants
- 100
Sites
- Site Name
- Pfizer Clinical Research Unit
- Contact Person Name
- Josué Mfopou Kunjom
- Contact Person Email
- PfizerVolRecruitment@pfizer.com
Sponsor
Primary sponsor
- Full Name
- Pfizer Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- PF-08065010
Related trials
Other published trials that may interest you.
- BELIMUMAB for Antibody-mediated rejection (kidney transplant)|High HLA sensitization (transplant candidates)
- Belimumab for Systemic lupus erythematosus
- INEBILIZUMAB for Myasthenia gravis
- PREDNISONE for Granulomatosis with polyangiitis (Wegener's) | Microscopic polyangiitis | ANCA-associated vasculitis
- BIRCH POLLEN ALLERGOID GLUTARALDEHYDE MODIFIED for Allergic rhinitis due to birch pollen | Allergic rhinoconjunctivitis